FDA declined to approve ivonescimab for lack of significant overall survival. Here's what the CRL says, what's still unknown, and the lessons for sponsors.
FDA launched a Rare Disease Framework Initiative with comments open to Dec 11. Here's what it builds on, what isn't changing, and what sponsors should do.